Log in | Register

Pharmaceutical Companies

Veloxis Pharmaceuticals to Restructure and Cut Staff

3 hours ago | News

Veloxis Pharmaceuticals A/S today announced that it contemplates restructuring the company's operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-TacroT, Veloxis' product candidate for the prevention of organ rejection.

Chelsea Therapeutics Sees Possible Northera Delay

3 hours ago | News

CHARLOTTE, N.C. (AP) — Chelsea Therapeutics International Ltd. said Tuesday it may have to make changes to a clinical trial of its drug candidate Northera, potentially delaying its approval.  

Pfizer Names New President and General Manager, Emerging Markets and Established Products Business Units and New President and General Manager, Primary Care

3 hours ago | News

Pfizer Inc. named Olivier Brandicourt as President and General Manager of the Emerging Markets and Established Products Business Units, effective June 1, 2012.

PPD Names David Simmons Chairman and CEO

3 hours ago | News

Pharmaceutical Product Development, LLC (PPD) today announced that its board of directors has named David Simmons chairman and CEO.

InterMune to Divest Actimmune

23 hours ago | News

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited to sell its rights to Actimmune® (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

FDA Says Xarelto Reduced Deadly Heart Attacks

May 22 | News

WASHINGTON (AP) — The Food and Drug Administration said Monday that a blood thinner from Johnson & Johnson appears to reduce life-threatening blood clots in high-risk patients, although it also increases the risk of internal bleeding.  

Alexion Pharmaceuticals Added to S&P 500 Index

May 22 | News

NEW YORK (AP) — Standard & Poor's Indices said Monday that it is adding the stock of drug developer Alexion Pharmaceuticals Inc. to its S&P 500 index.  

Medivation and Astellas Announce Submission of Prostate Cancer NDA

May 22 | News

Medivation, Inc. and Astellas Pharma Inc. announced that Medivation has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for enzalutamide (formerly MDV3100). The compound has been studied in patients with castration-resistant prostate cancer who have received docetaxel therapy.  

Outsourcing Clinical Research: Established vs. Emerging Markets

Outsourcing Clinical Research: Established vs. Emerging Markets

May 21 | Articles

In recent years, emerging markets have been touted as an affordable and attractive labor pool for the outsourcing of pharmaceutical and biotechnology projects.

Baxter Facilities Recognized for Safe Handling of Potent Compounds

May 21 | News

Baxter facilities in Halle and Bielefeld, located in Germany's Westfalen region, have been recognized and certified for their capabilities in handling potent pharmaceutical compounds by SafeBridge Consultants, Inc., a leading occupational health and safety consulting firm.  Baxter is...

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter